<DOC>
	<DOCNO>NCT02180503</DOCNO>
	<brief_summary>Investigation relative bioavailability 1 mg 10 mg BI 1356 BS PIB reconstitute 0.1 % tartaric acid vs. 1 mg 10 mg BI 1356 BS tablet include food effect 10 mg tablet dose group</brief_summary>
	<brief_title>Relative Bioavailability 1 mg 10 mg BI 1356 BS Powder Bottle ( PIB ) 1 mg 10 mg BI 1356 BS Tablets Single Oral Administration Healthy Male Volunteers Including Influence Food Bioavailability 10 mg BI 1356 BS</brief_title>
	<detailed_description />
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test No finding deviate normal clinical relevance No evidence clinically relevant concomitant disease Age ≥21 Age ≤65 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen study centre No adequate contraception ( condom use plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug one month last intake</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>